MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance.
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...
The UAB Molecular Genetic Pathology Fellowship Program is participating in the Molecular Genetic Pathology Unified Timeline for the 2025-2026 fellowship year. For ...
Cancer diagnosis can be challenging, and delayed diagnosis can allow cancer to progress, complicating treatment. Oral ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
BOSTON--(BUSINESS WIRE)--Invicro LLC, and Ambry Genetics, both Konica Minolta precision medicine companies and leading providers of quantitative biomarker and genomic profiling services, today ...
Granted, vacated, and remanded in light of <em><a href=https://www.scotusblog.com/case-files/cases/mayo-collaborative-services-v-prometheus-laboratories-inc/>Mayo ...
The Alzheimer's risk gene APOE ε4 drives the aggressive, brain-wide Type 2 subtype of ALS, causing cognitive decline.
VICTORY! On June 13, 2013, the U.S. Supreme Court invalidated patents on two genes associated with hereditary breast and ovarian cancer in response to a lawsuit filed by the American Civil Liberties ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results